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Abstract
Commonly held dietary guidelines discourage full-fat dairy consumption
due its to high levels of saturated fatty acids, which are believed to aversely
influence cardiovascular disease risk. Cardiovascular diseases cause more
than one third of deaths in the developed world. With dairy often providing
a large part of energy and nutrients in Western diets, research into its effects
on human health is warranted.
Several recent studies have suggested a protective role of dairy in the
development of cardiometabolic disease. However, many of these have
used imprecise methods of dietary assessment, based on questionnaires or
interviews. Biomarkers are emerging as a means of evaluating diet in a more
objective way.
Currently used dairy fat biomarkers are minor fatty acid constituents of
dairy that preferably are unique to dairy and not influenced by endogenous
metabolism. These compounds can be measured in blood or adipose tissue
samples, and can be good indicators of short (weeks) and long (years) term
intakes, depending on the sampling medium. The most reliable indicator of
dairy fat intake seems to be pentadecanoic acid (C15:0), however research in
this area is somewhat lacking.
Studies where these biomarkers have been evaluated in relation to car-
diometabolic disease endpoints (incident cardiovascular disease or type-2
diabetes) have generally found dairy to elicit a protective effect. Cross-
sectional studies evaluating indices of the metabolic syndrome suggest that
dairy fat may slow down disease progression.
Further standardization of methodologies and validation of biomarker
concentrations in relation to intake could improve reliability of biomarker-
based dietary assessments. Furthermore, combining chemical and traditional
methods could provide even better precision than using either method alone.
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Sammanfattning
Många av dagens kostråd avråder från konsumtion av fullfeta mejeriproduk-
ter p.g.a. höga halter mättade fettsyror, vilka anses påverka kardiovaskulär
hälsa negativt. Hjärt–kärlsjukdomar orsakar mer än en tredjedel av alla
dödsfall i den industrialiserade världen. Då mejeriprodukter ofta bidrar med
en betydande del av energi och näringsämnen i den västerländska kosten är
det motiverat att studera dess effekter på human hälsa.
Ett antal studier har de senaste åren funnit resultat som antytt att kon-
sumtion av mejeriprodukter kan ha en skyddande inverkan på risken för
insjuknande i hjärt–kärlsjukdom, men många av dessa har använt osäkra
metoder för att mäta deltagarnas kostvanor. Mer precisa mätningar kan göras
med biomarkörer, något som ökat i användning under senare tid.
De biomarkörer för mjölkfettintag som används i dag är fettsyror som
förekommer i låga halter i mjölken, och som bör vara både unika för mej-
eriprodukter och inte påverkade av endogen metabolism. Dessa ämnen kan
mätas i blod eller i fettvävnad, och kan vara goda indikatorer för konsumtion
över korta (veckor) eller långa (år) perioder. En av de mest tillförlitliga
markörerna anses vara pentadekansyra (C15:0), men ytterligare forskning
behövs för att säkerställa detta.
Studier som utvärderat dessa biomarkörer i förhållande till kliniska änd-
punkter (incidens av hjärt–kärlsjukdom eller diabetes typ 2) har generellt
visat på en skyddande effekt. Tvärsnittsstudier som undersökt olika aspekter
av metabola syndromet antyder att mjölkfettskonsumtion kan fördröja dess
utveckling.
Ytterligare standardisering av metoder och validering av samband mel-
lan biomarkörer och intag skulle kunna förbättra precisionen hos kemiska
kostskattningsmetoder. Precisionen skulle ytterligare kunna förbättras om
kemiska och traditionella metoder kombinerades.
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Acronyms and abbreviations
BCAA Branched-chain amino acid
CE Cholesteryl ester
CHD Coronary heart disease
CRP C-reactive protein
CVD Cardiovascular disease
FA Fatty acid
FFQ Food frequency questionnaire
HDL-C High density lipoprotein cholesterol
HR Hazard ratio
MetS Metabolic syndrome
MI Myocardial infarction
OR Odds ratio
PL Phospholipid
RR Relative risk
rTFA Ruminant trans fatty acid
SFA Saturated fatty acids
T2D Type-2 diabetes
TC Total cholesterol
TAG Triacylglycerol
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1 Introduction
Milk and dairy products are important sources of energy and nutrients in
large parts of the Western world. In a Swedish study conducted in 2010–2011
(Amcoff et al., 2014), dairy products (excluding butter, and dairy used in
cooking) provided 12 % of calories and 11 % of protein present in the diet.
Additionally, dairy products supplied almost a fifth of the average daily
intake of protein, and was a rich source of several vitamins and minerals
including vitamins A and D, calcium, and phosphorus.
Dairy is also a rich source of saturated fatty acids (SFA), with dairy
products and cheese supplying 25 % of the SFA intake (ibid.). However,
since this value neither accounts for butter nor for dairy products used
for cooking, the true amount is likely higher. Because SFA is generally
considered harmful to cardiovascular and metabolic health, many Western
dietary guidelines have focused on encouraging the substitution of reduced-
fat dairy products for full-fat varieties. Choosing reduced-fat varieties is seen
a means of reducing the consumption of saturated fat without adversely
affecting intakes of other nutrients (Nordic Council of Ministers, 2014; U.S.
Department of Agriculture and U.S. Department of Health and Human
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Services, 2010; Krauss et al., 2000).
The metabolic syndrome (MetS) is a cluster of risk factors for heart
disease and diabetes, which includes high blood pressure, dyslipidemia (high
triglycerides and low HDL-C), raised fasting glucose, and central obesity
(Alberti et al., 2009). Persons with MetS are at higher risk of heart disease and
diabetes (ibid.), implying a common etiology for these diseases. Therefore,
these diseases (coronary heart disease (CHD), stroke, and type-2 diabetes
(T2D)) are often known as cardiometabolic diseases, encompassing both
cardiovascular and metabolic disease. Strengthening the idea of a common
etiology is the fact that association between an important component of
MetS, raised fasting glucose, is part of the diagnostic criteria for T2D (Amer-
ican Diabetes Association, 2008), but MetS is also a risk factor for CVD
independently of T2D (Malik et al., 2004).
Researching the impact of dairy consumption on human health is a
complex task, fraught with methodological issues. Practical and financial
considerations limit the feasibility of conducting large-scale randomized
controlled trials, and studies of this kind generally measure surrogate mark-
ers, e.g. blood lipid profiles, and not clinical endpoints such as incident
heart disease. Prospective cohort studies can use clinical endpoints, but the
assessment of subjects’ diets is generally imprecise (especially over extended
periods of time). Due to these issues, the interest in using biomarkers, specific
chemical indicators of diet, has increased among nutritional epidemiologists
(Van Dam and Hunter, 2012).
The aim of this thesis is, first of all, to provide an overview of the use
of biomarkers in studies of dairy intake and, secondly, to summarize the
findings of studies that employ biomarkers to elucidate how dairy intake
relates to outcomes of cardiometabolic health.
2 Dairy biomarkers
2.1 Biomarkers versus traditional methods of diet assessment
When using epidemiological methods to determine the influence of dietary
factors on human health, the accuracy of dietary assessment is of the utmost
importance. Potential systematic biases influencing the validity of dietary
reporting by subjects include over- and underestimation of intake, subjects
adjusting reported intake in accordance with what one believes is healthy
or is “what the investigator wants to hear”, and difficulty in remembering
food choices over extended periods of time (Willett, 2012). Even the most
comprehensive method of assessment, the weighed food record, where sub-
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jects weigh all food consumed, may not be applicable for ascertainment of
long-term intakes due to the high practical overhead associated with subjects
weighing all their food.
Dietary biomarkers have their limitations as well. Subjects’ levels of
biomarkers can be influenced by many factors, including genetics, disease sta-
tus, age, nutrient bioavailability, the specific depot that is being sampled, etc.
(Hodson et al., 2008; Van Dam and Hunter, 2012; Arab, 2003). Optimally,
biomarkers should be combined with other methods of measuring dietary
intake to strengthen the conclusions and minimize bias, since measurement
errors inherent to either method arise independently of each other (Van Dam
and Hunter, 2012; Baylin et al., 2002).
2.2 Compounds used as biomarkers
The most common biomarkers used for assessing dairy intake are the odd-
numbered saturated fatty acids (FA) pentadecanoic acid (15:0) and margaric
acid (17:0). These FAs are microbially synthesized in the rumen and passed
on to the milk, and they cannot be endogenously synthesized by humans.
Several studies have found 15:0 to be a valid biomarker (Wolk et al., 1998;
Smedman et al., 1999; Wolk et al., 2001), but correlations have generally
been weaker and less consistent for 17:0 (Nestel et al., 2014; Jacobs et al.,
2014).
Myristic acid (14:0) has been suggested as a dairy fat biomarker that
is easier to measure, due to the higher concentrations normally present
in human FA pools. 14:0 is abundant in dairy and ruminant fat, but is
otherwise scarce in the food supply. Although dietary intake of this FA may
thus correlate with dairy fat consumption, circulating (i.e. present in blood)
or adipose (fat) tissue levels may not. Being an even-chained FA, endogenous
synthesis can be an important confounder. Wolk et al. (2001) found 14:0 to
be an adequate biomarker in adipose tissue but not in cholesteryl ester (CE)
and phospholipids (PL), and several other studies have reported inconsistent
results when comparing 14:0 and 15:0 to the same outcomes (c.f. Perreault
et al. (2014); de Oliveira Otto et al. (2013); Iggman et al. (2010)). Since
endogenous synthesis can be upregulated in metabolic disease, as evidenced
by elevated triglyceride levels, the use of this biomarker can be problematic
when studying cardiometabolic outcomes or risk factors.
Another marker that has been evaluated in a number of studies (c.f.
Mozaffarian et al. (2010, 2013); de Oliveira Otto et al. (2013)) is the ruminant
trans fatty acid (rTFA) trans-palmitoleic acid (trans-16:1n–7), which cannot
be synthesized endogenously. However, this fatty acid can also be formed
by partial hydrogenation of vegetable oils, which can limit its validity as a
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biomarker. In a study on the Multi-ethnic Study of Atherosclerosis (MESA)
cohort, trans-16:1n–7 was found to be more strongly associated with french
fry consumption than with any other food (de Oliveira Otto et al., 2013).
Other minor FA constituents have also been used. Conjugated linoleic
acid (conjugated 18:2; CLA) isomers were validated in a Swedish population
(Jiang et al., 1999), where the 9c , 11t isomer was found to correlate more
strongly with dairy fat intake than with 15:0 in adipose tissue. Smit et al.
(2010) used this isomer as a biomarker for the intake of dairy fat from cows
grazing on pasture, as opposed to silage or grain.
Recently, trans-18:1 isomers have been demonstrated to correlate with
milk consumption in Chinese subjects (Zong et al., 2014; Yu et al., 2012).
As with other trans FAs, hydrogenated vegetable oils are likely confounders
here as well (Micha et al., 2010).
2.3 The use of tissues and blood for sampling
The biomarkers described above are fatty acid components of dairy fat. For
biomarker analysis, either adipose tissue or blood samples are taken from
the subjects. Adipose tissue is believed to be the best indicator of long-term
intake, with studies estimating t1/2 values of 6–24 months for adipose tissue
triacylglycerol (TAG) (Hodson et al., 2008).
Serum or plasma samples are generally analyzed for FA composition
of free or total PL, erythrocytes (red blood cells), non-esterified fatty acids
(NEFA), TAG or CE FAs. An issue with sampling serum FA composition is
that it likely does not correlate with long-term intake as closely as samples
from adipose tissue do. Even erythrocytes, previously believed to reflect
120-day average intakes (Arab, 2003), have been demonstrated to alter their
membrane FA composition in response to diet in a matter of days (Hodson
et al., 2008). In a study by Wolk et al. (2001), weaker correlations were
found for serum PL and cholesteryl esters and dietary dairy fat intake than
for adipose tissue FAs, especially for 14:0. In a recent study (Hodson et al.,
2014), plasma CE, TAG, PL and erythrocytes were found to be equally valid
indicators of 15:0 over a similar time period, equilibrating after two weeks
on a high-SFA diet.
Blood sampling has been considered less invasive than adipose tissue
sampling, due to the requirement of a biopsy when performing the latter.
However, Beynen and Katan (1985) has reported on the use of a less invasive
method for sampling adipose tissue. In this method, a “mini biopsy” is
performed via aspiration into a 1.5 mm diameter needle, thereby reducing
intrusiveness and lessening requirements for operator training. This method
should be considered when more reliable measures of long-term dairy fat
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intake are needed, if the study protocol allows it.
2.4 Other methodological considerations
Although less representative of long-term intake than adipose tissue samples,
serum samples can be used for nested case–control studies. In this type of
study, blood is drawn from all subjects in a large cohort, but samples are
analyzed only after a certain number of cases are present in the cohort, or
after a predetermined period of time. At this time, risk factor matched
controls are chosen from the cohort according to a certain case:control
ratio, often 1:2. The use of biomarkers makes accurate retrospective dietary
assessment feasible, even for deceased subjects. Post hoc analysis of blood
samples also reduces laboratory costs.
It is worth noting that measures of dairy intake can differ between
traditional and biomarker-based methods of dietary assessment in a number
of ways. First, dairy biomarkers are indicative of total dairy fat consumption,
which may or may not reflect total dairy intake. This also means that high-
fat products will influence biomarker concentrations more than low-fat
products. Second, since these biomarkers are measures of total dairy fat
intake, food items which are normally hard to quantify using traditional
methods, e.g. cheese on pizza or butter in mashed potatoes, will influence
biomarker concentrations as well. Third, levels of individual fatty acids in
dairy are dependent on animal husbandry practices, primarily the type of
feed used (Kratz et al., 2013). Finally, fatty acid biomarkers are a relative
measure of fatty acid intake, and cannot be used for quantitative assessment.
Dairy biomarkers are present not only in dairy, but also in adipose tissue
and intramuscular fat of ruminants. Thus, dairy is not the only dietary
source for these FAs. However, since the intake of dairy fat generally far
exceeds the intake of ruminant fat from meat in most Western countries,
the risk of confounding is likely minor. Although not usually an issue in
Western populations, one should take other dietary sources into account
when examining populations with other dietary habits.
3 Bioactive compounds in dairy products
Bioactive compounds are compounds which have an effect on living tissue.
This is a very broad concept, especially since any type of food can arguably
fall under this definition, so for practical purposes, bioactivity will be referred
to as the effects caused beyond those that could be expected from metabolism
alone.
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A large part of dairy fat is made up of SFA. For several decades, SFA
consumption has been discouraged by policymakers and nutritionists, due to
its observed correlation with CVD (Keys et al., 1986). However, recent meta-
analyses of prospective cohort studies have detected either inverse or neutral
associations between SFA consumption and CVD (Siri-Tarino et al., 2010;
Chowdhury et al., 2014). Additionally, recent publications have found in-
verse associations between dairy consumption and CVD (Soedamah-Muthu
et al., 2011), as well as for incident T2D (Gao et al., 2013). Moreover, physio-
logical effects of SFA vary with chain length. For example, medium-chain
fatty acids (C5–C12) are taken up via the portal vein and are preferentially
β-oxidized in the liver (Bach and Babayan, 1982). Short chain (C2–C4) SFAs
are absorbed by enterocytes and provide energy as well as downregulating
inflammatory pathways in these cells (Kratz et al., 2013).
More than 400 different individual FAs have been identified in dairy
(Jensen, 2002), of which some have been demonstrated to exhibit physio-
logical activity. Examples of bioactive fatty acids in dairy are conjugated
linoleic acids (in particular the 9c , 11t and 10t , 12c isomers), rTFAs, branch-
ed-chain fatty acids such as phytanic acid (Kratz et al., 2013), and trans-16:1
n–7 (Mozaffarian et al., 2010, 2013). Due to the large number of identified
FAs, there are likely several that have yet to be classified as bioactive.
Dairy provides around 11 % of total protein in the Swedish diet (Amcoff
et al., 2014), again only counting direct consumption. Dairy protein is highly
bioavailable, and may benefit cardiometabolic health in several ways. It has
been shown to improve metabolic risk factors such as hypertension (high
blood pressure) and dyslipidemia (abnormal blood lipids) (McGregor and
Poppitt, 2013). In addition, protein consumption, especially branched-chain
amino acids (BCAA) and in particular leucine, is known to stimulate protein
synthesis and improve body composition, which can be of importance for
preventing the development of MetS (ibid.). In a recent study comparing the
effects of diet on weight regain after weight loss, Bendtsen et al. (2014) found
a non-significant (p = 0.08) association between dairy protein intake and
weight regain. Although this effect was attenuated after adjusting for total
protein intake, suggesting that the source of protein was not the determinant
for weight regain in this study, it is plausible that regular dairy consumption
is associated with higher protein intake.
Calcium and vitamin D, which are present in many dairy products, are
also potentially beneficial to cardiometabolic health. In a review of the
influence of these nutrients on energy balance, Soares et al. (2014) concluded
that both nutrients influence human energy regulation positively. According
to the authors, the evidence for the beneficial effects of vitamin D is largely
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based on cross-sectional studies showing an inverse correlation between
vitamin D status and obesity, which could be confounded by dilution of the
vitamin into a larger adipose tissue mass. In a meta-analysis of randomized
controlled trials, Onakpoya et al. (2011) found that calcium supplementation
of 1000–1500 mg day−1 led to small but significant changes in body weight
and body fat, with trials ranging from 6–24 months in duration. Calcium-
induced fat loss also seems to favor visceral fat depots (Soares et al., 2014),
which can be of certain importance for preventing cardiometabolic disease.
In a meta-analysis of prospective studies and randomized trials conducted by
Wang (2010), vitamin D, but not calcium, was found to be associated with a
reduced risk of developing cardiovascular disease.
Dairy products are diverse, owing to the versatility of milk. Milk can
be consumed whole, containing protein, fat, and carbohydrate along with
minerals and vitamins in more or less the original proportions. More often,
dairy is processed into one of many end products. For example, separation
by centrifugation renders skim milk and cream, with each fraction con-
taining any potentially bioactive compound associated with either phase
(hydro- or lipophilic). In cheesemaking, dairy proteins are separated based
on coagulation properties, thus cheese contains only the coagulative casein
protein fraction. The whey fraction is then used in products such as protein
powder or ice cream. Fermentation further alters the nutritional and chemi-
cal composition. Due to this diversity, the health effects of dairy can differ
by the type of product consumed, further complicating research into any
potential health effects.
A thorough review of all known bioactive compounds potentially pres-
ent in dairy products is outside of the scope of this thesis, but there are
several reviews published on the subject, c.f. Haug et al. (2007); Kratz et al.
(2013). In addition to process-induced changes in composition, the issue of
the bioactive properties of milk is further complicated by the fact that levels
of many compounds, in either individual products or total intake, can be
influenced by factors such as feeding regime, genetics, culture and climate
(via a preference for certain products over others), etc. However, this section
serves to demonstrate the nutritional heterogeneity of these products. One
must also take into account that at least some compounds can be beneficial
to health only where an insufficiency is present, as can be the case for several
vitamins and minerals.
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4 Studies evaluating dairy biomarkers
4.1 Study selection
To find pertinent studies, MEDLINE was searched using the terms “fatty acid
composition”, “dairy”, “biomarkers”, and names of relevant biomarker com-
pounds in combination with “cardiovascular”, “coronary”, and “diabetes”.
Moreover, review articles and meta-analyses on either dairy consumption
or circulating fatty acid composition and cardiometabolic disease outcomes
were identified, and their reference lists examined for relevant studies.
A similar strategy was used for finding studies relevant to different aspects
of the metabolic syndrome. However, due to the many facets of metabolic
health that can be measured, an exhaustive list of such studies is outside the
scope of this thesis. Since most studies of this kind are cross-sectional in
design, one cannot infer causality from their results. Rather, the studies have
been selected to be representative of the literature on the subject as a whole,
and as a basis for discussing the results from studies using clinical endpoints
presented below.
4.2 Dairy biomarkers and metabolic health
As described above, the diagnosis of MetS is based on metabolic and an-
thropometric measures that exist on a continuum. Therefore, emergence of
disease within subjects can be tracked, as opposed to simply estimating the
increased risk of disease.
Nine studies measuring both dairy biomarkers and indices of cardiometa-
bolic health are included in this overview (Table 1). All experiments were
cross-sectional in design, which means that they cannot be used for deducing
causality.
Two publications evaluated the correlation between dairy fat biomarkers
and prevalence of MetS. Maruyama et al. (2008) examined the FA composi-
tion of plasma PL in 165 males aged 40–59. Subjects receiving medication
for MetS-related complications were excluded from this study. Out of 165
subjects, 27 were subsequently diagnosed as having untreated MetS. Levels
of 15:0 and 17:0 were lower in subjects with MetS, compared to MetS-free
subjects. Additionally, negative correlations were found between plasma
17:0 and HDL-C, body fat percentage, and triglycerides. Mayneris-Perxachs
et al. (2014) found a strong positive correlation for plasma 14:0 and MetS
prevalence, but this correlation was not present for 17:0. The aim of the
latter study was not explicitly to measure dairy biomarkers, which explains
the use of the less reliable markers 14:0 and 17:0.
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Table 1: Studies examining dairy biomarkers and indices of metabolic health.
Abbreviations: FA, fatty acid; LH, lean healthy; MetS, metabolic syndrome; MHO, metaboli-
cally healthy obese; MUO, metabolically unhealthy obese; NEFA, non-esterified fatty acid;
PL, phospholipid
Citation Biomarkers Outcomes Subjects Main findings
Maruyama et al.
(2008)
PL 14:0, 15:0
and 17:0 in
serum.
FA profiles of sub-
jects with and without
previously undiagnosed
MetS.
Males aged 40–59
years, with (n = 27)
and without (n =
138) MetS.
15:0 and 17:0 concentrations
were lower in subjects with
MetS.
Mozaffarian et al.
(2010)
PL t-16:1n–7 in
plasma.
Cardiometabolic risk
markers, incident T2D.
3736 adults. t-16:1n–7 was associated
with favorable changes in car-
diometabolic risk markers.
Iggman et al.
(2010)
Multiple FAs in
adipose tissue.
Insulin sensitivity. 795 men, mean age
71 years.
14:0 and 17:0, but not 15:0,
correlated positively with in-
sulin sensitivity.
Wang et al.
(2011)
PL 15:0 and 17:0
in serum.
Markers of inflam-
mation and oxidative
stress.
305 adolescents,
mean age 15 years.
Most dairy biomarkers were
associated with lower levels
of inflammation in obese sub-
jects. Only IL-6 was associ-
ated with dairy biomarkers
in all subjects.
Kratz et al.
(2014)
PL and NEFA
15:0, 17:0, and
t-16:1n–7 in
plasma.
Glucose tolerance. 17 men and women
with NAFLD, 15
age- and BMI-
matched controls.
Several biomarkers were as-
sociated with increased glu-
cose tolerance.
Jacobs et al.
(2014)
15:0, 17:0, and
t-16:1n–7 in ery-
throcytes.
Markers of dyslipi-
demia.
1759 random sub-
jects from EPIC-
Potsdam study, age
35–64.
Weak or no association for
most dairy biomarkers and
dyslipidemia.
Mayneris-
Perxachs et al.
(2014)
NEFA 14:0 and
17:0 in plasma.
Presence of MetS. 427 subjects aged
55–80 years.
Strong positive correlation
between 14:0 and MetS, 17:0
neutral.
Nestel et al.
(2014)
PL 14:0, 15:0,
t-16:1n–7, 17:0,
and t-18:1n–7 in
plasma.
Insulin sensitivity. 86 overweight and
obese subjects
with metabolic
syndrome.
Dairy biomarkers were asso-
ciated with favorable mea-
sures of insulin sensitivity.
Yu et al. (2012) t-18:1 in erythro-
cytes.
Several indices of
cardiometabolic health,
prevalence of T2D.
3107 subjects aged
50–70 y.
t-18:1 was inversely corre-
lated with all indices of car-
diometabolic health except
hypertension.
Perreault et al.
(2014)
Total 14:0,
15:0, 17:0, and
t-18:1n–7 in
serum.
FA profiles of unhealthy
vs. healthy subjects.
LH, MHO and MUO
subjects (n = 10 per
group).
Significantly higher concen-
tration of 14:0 in MUO than
LH or MHO.
Insulin sensitivity and glucose tolerance are important factors of MetS.
Three studies that examined relationships between dairy biomarkers and
these factors are included in this overview. Iggman et al. (2010) examined
adipose tissue 14:0, 15:0, and 17:0 in 795 older Swedish men, and compared
it to insulin sensitivity as measured by the “gold standard” euglycemic clamp
method (Kratz et al., 2013). In the fully adjusted model (BMI, smoking,
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alcohol intake and physical activity), 14:0 and 17:0, but not 15:0, were
associated with increased insulin sensitivity, but the authors mention that
there might have been methodological errors which could have influenced
their measurements. In a recent study, Kratz et al. (2014) measured insulin
sensitivity in 17 subjects with non-alcoholic fatty liver disease (NAFLD; an
affliction closely related to MetS) and 15 age- and BMI-matched controls,
and examined correlations with 15:0, 17:0 and trans-16:1n–7 in plasma PL
and NEFA. In this investigation, all dairy biomarkers in PL were found to
be associated with favorable changes in glucose metabolism. In the third
study (Nestel et al., 2014), glucose tolerance was measured in 86 overweight
and obese subjects with MetS. Most dairy biomarkers (15:0, trans-16:1n–7,
and trans-18:1n–7, but not 17:0) were found to be positively correlated with
glucose tolerance.
Other researchers have looked at a number of components of MetS in
relation to dairy biomarkers. Mozaffarian et al. (2010) measured plasma PL
levels of t-16:1n–7 in 3736 adults aged 65 or older, and evaluated correlations
with markers of metabolic health. Comparing extreme quintiles of trans-
16:1n–7 levels, subjects in the highest quintile had lower waist circumference
(p = 0.009), lower total cholesterol (TC):HDL-C ratio (p < 0.001), less
insulin resistance (p < 0.001), and lower levels of C-reactive protein (CRP; a
marker of inflammation, p = 0.050). These findings suggest better metabolic
health in the highest quintile of dairy intake. Measures of blood glucose,
insulin concentrations and triglycerides were also favorable for the highest
quintile, though bias is likely present due the fact that many samples were
taken when the subjects were not in a fasting state.
Jacobs et al. (2014) examined correlations between dairy biomarkers
(15:0, 17:0 and t-16:1n–7) in erythrocytes and a number of markers for
dyslipidemia in 655 men and 1104 women. The results of this study suggest
that dairy intake is not correlated with most aspects of dyslipidemia in
men, but that several markers correlate with a favorable lipidemic profile in
women. However, many measures of dyslipidemia are influenced by fasting
status, which was not consistent among subjects in this study. Overall, the
findings were inconclusive regarding dairy biomarkers, which might be
at least in part attributable to the pronounced heterogeneity between the
male and female groups (Jacobs et al., 2014, Table 1), as well as heterogenous
fasting status (which was not included in multivariate analyses). Additionally,
25 % of the subjects were excluded due to “implausible” values of erythrocyte
FAs, suggesting further methodological issues.
An uncommon biomarker, trans-18:1 (all isomers), was used in a rela-
tively large study (n = 3107) conducted on a Chinese population (Yu et al.,
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2012). The authors evaluated associations between extreme quintiles of
erythrocyte trans-18:1 and several indices of cardiometabolic health, includ-
ing markers of dyslipidemia, insulin resistance, hypertension, and central
obesity, as well as the prevalence of T2D. For extreme quartiles, all indices
except hypertension were inversely correlated with erythrocyte trans-18:1
concentrations.
Finally, in a recent study by Perreault et al. (2014), serum FA profiles
of groups of lean healthy (LH), metabolically healthy obese (MHO), and
metabolically unhealthy obese (MUO; n = 10 for each group) were measured.
MHO and MUO groups did not differ in anthropometric measurements,
but were distinguished by cardiometabolic risk profiles. FA biomarkers of
interest to this thesis were 14:0 and 15:0. Only 14:0 showed a consistent
trend, with elevated levels in the MUO group compared to both LH and
MHO. Since 14:0 might be confounded by metabolic disease, these results
might be irrelevant to the question at hand, especially considering the small
number of subjects.
4.3 Cardiovascular disease outcomes
Cardiovascular diseases (CVD) are diseases of the heart and circulatory sys-
tems, and include both CHD and stroke, as well as heart failure (HF). CHD
diseases share a common etiology in the inability of the coronary arteries
to deliver sufficient oxygen to the heart, commonly due to atherosclerosis.
A common type of CHD is myocardial infarction (MI), commonly known
as a heart attack. Strokes are caused by a temporary lack of oxygen supply
to parts of the brain, often stemming from either blocked arteries or brain
hemorrhages.
Ten studies were found that evaluated associations between biomarkers
of dairy fat intake and cardiac event endpoints. Of these, two were prospec-
tive cohort studies and eight were nested case–control studies. All except
two used plasma or serum biomarkers, and all except one measured 15:0
concentrations (Table 2).
Of the nine studies measuring 15:0 concentrations, five found inverse
correlations for cardiac events, and three did not find any significant correla-
tions. In one study (Sun et al., 2007), plasma 15:0 was found to be strongly
associated with CHD in the fully-adjusted model (OR for extreme tertiles:
2.36, 95% CI: 1.16–4.78, pt r end = 0.03). However, this association was not
found for erythrocytes (OR: 0.93, 95% CI: 0.42–2.05). Additionally, 17:0
was associated with a protective effect in erythrocytes, but not in plasma. It
is likely that the discrepancy between plasma and erythrocyte biomarker
associations is an artifact stemming from a methodological problem, likely
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Table 2: Studies examining dairy biomarkers and incident cardiovascular disease.
Abbreviations: CE, cholesteryl ester; CHD, coronary heart disease; CLA, conjugated linoleic
acid; CVD, cardiovascular disease; HF, heart failure; MI, myocardial infarction; OR, odds
ratio; PL, phospholipid
Citation Biomarkers Outcomes Subjects Main findings
Aslibekyan et al.
(2012)
15:0 and 17:0 in adi-
pose tissue.
Incident first MI. 1815 cases, 1815
matched controls.
No significant correlations.
de Oliveira Otto
et al. (2013)
PL 14:0, 15:0, and
t-16:1n-7 in plasma.
Incident CVD. 2837 (cohort), 189
cases.
Inverse correlation between
15:0 and CVD.
Khaw et al.
(2012)
Odd chain SFA com-
position in plasma
PL.
Incident CHD. 2424 cases, 4930
matched controls.
Inverse correlation between
15:0, 17:0 and CHD.
Warensjö et al.
(2010)
PL 15:0 and 17:0 in
serum.
Incident MI. 444 cases, 556 con-
trols.
No significant associations.
Smit et al.
(2010)
9c , 11t -CLA in adi-
pose tissue.
Incident MI. 1813 cases, 1813
matched controls.
OR for extreme quintiles =
0.51.
Warensjö et al.
(2009)
PL 15:0 and 17:0 in
plasma.
Incident stroke. 129 cases, 257
matched controls.
17:0 and (15:0 + 17:0) were
inversely associated with in-
cident stroke.
Yamagishi et al.
(2008)
PL and CE 14:0,
15:0, and 17:0 in
plasma.
Incident HF. 3592 (cohort), 197
cases.
15:0 and 17:0 in PL were neg-
atively associated with HF,
whereas 14:0 in CE was posi-
tively associated, but results
for 15:0 and 17:0 were not
significant after multivariate
adjustment.
Sun et al. (2007) 15:0, 17:0, and t-
16:1n-7 in plasma
and erythrocytes.
Incident CHD. 166 cases, 327
matched controls.
15:0 in plasma, but not in
erythrocytes, correlated pos-
itively with incident CHD.
17:0 in erythrocytes was in-
versely correlated.
Biong et al.
(2006)
14:0, 15:0, and 17:0
in adipose tissue.
Incident first MI. 99 cases, 98
matched controls.
15:0 inversely associated
with incident first MI.
Warensjö et al.
(2004)
CE and PL 15:0 and
17:0 in serum.
Incident first MI. 78 cases, 156
matched controls.
15:0 and 17:0 in serum
PL were inversely associated
with incident first MI.
due in part to the heterogenous fasting status among subjects.
Smit et al. (2010) measured 9c , 11t -CLA in adipose tissue. The authors
state that this biomarker is indicative of pasture-fed dairy consumption,
however, no measures of 15:0 were performed to separate putatively CLA-
rich products from conventional dairy. In this study, adipose tissue CLA
was strongly and significantly associated with reduced risk of MI (OR for
extreme quintiles: 0.51, 95% CI: 0.36–0.71, p < 0.0001), as well as with total
dairy intake (p < 0.0001).
Eight of the studies measured 17:0 concentrations. Of these, five found
inverse correlations with cardiac events, and three found no significant cor-
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relations. It is worth noting that although 17:0 is generally less strongly
correlated with dairy fat intake, it is often generally found to be inversely
associated with CVD risk, perhaps indicative of unknown metabolic pro-
cesses.
Regarding associations for t-16:1n–7, associations were generally weak.
Sun et al. (2007) found a weakly significant (pt r end = 0.04) inverse correlation
for t-16:1n–7 in plasma and CHD in the basic multivariate model, but this
association lost significance in the fully adjusted model. Additionally, due to
the issues described above, the ambiguous results found in this study could
likely be influenced by fasting status. In the MESA cohort, no significant
association was found, but the authors state that t-16:1n–7 was likely a
marker for intake of partially hydrogenated vegetable oils in these subjects,
as indicated by FFQ results (de Oliveira Otto et al., 2013).
4.4 Diabetes outcomes
Type-2 diabetes (T2D) is a disease of impaired glucose tolerance, resulting
either from reduced production of or from impaired sensitivity to insulin.
The disease is diagnosed as either having a plasma fasting glucose level of
≥ 7.0 mmol l−1, or a plasma glucose level of ≥ 11.1 mmol l−1 two hours
after an oral glucose tolerance test (American Diabetes Association, 2008).
Three studies were identified that employed dairy biomarkers and used
incident T2D as a main outcome. All found strong significant inverse associ-
ations between dairy biomarkers and incident T2D (Table 3).
Table 3: Studies examining dairy biomarkers and incident type-2 diabetes.
Abbreviations: PL, phospholipid; T2D, type-2 diabetes
Citation Biomarkers Outcomes Subjects Main findings
Mozaffarian et al.
(2010)
t-16:1n-7 in plasma
PL.
Incident T2D. 3736 (cohort), 304
cases.
Significant inverse correla-
tion for t-16:1n-7 and inci-
dent T2D.
Mozaffarian et al.
(2013)
t-16:1n-7 in plasma
PL.
Incident T2D. 2281 (cohort), 205
cases.
Significant inverse correla-
tion for t-16:1n-7 and inci-
dent T2D.
Zong et al.
(2014)
t-18:1 in erythro-
cytes.
Incident T2D. 2091 (cohort), 504
cases.
Significant inverse associa-
tion for t-18:1 and incident
T2D.
In two studies, both conducted by Mozaffarian et al. (2010, 2013), t-
16:1n–7 levels were measured in plasma PL. In a meta-analysis including
subjects from both studies (Mozaffarian et al., 2013), the HR for extreme
quintiles was 0.44 (95% CI: 0.31–0.63, pt r end < 0.001).
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In a recent article, Zong et al. (2014) reports on erythrocyte t-18:1 con-
centrations in a cohort of middle-aged and older Chinese subjects. In this
cohort, dairy consumption was uncommon, with only 57.5% of participants
reporting any dairy consumption at all. t-18:1 was associated with total dairy
consumption, and the RR for T2D for extreme quartiles was 0.82 (95% CI:
0.65–1.04, pt r end = 0.02).
5 Discussion
A number of recent reviews and meta-analyses have found either inverse
or neutral associations for dairy consumption and cardiometabolic disease
outcomes (Kratz et al., 2013; Aune et al., 2013; Soedamah-Muthu et al.,
2011). However, many of the underlying studies have used FFQs for diet
assessment.
Unlike in drug trials, it is not possible to design a properly controlled,
randomized, double-blind trial examining the effects of dairy consumption
on human health. By definition, an isocaloric non-dairy control food cannot
be metabolically inert, and likely cannot be designed to have the sensory
properties required for proper blinding. Therefore, evidence from biomarker-
based studies should be considered very high-grade, especially when used in
studies of prospective cohort or nested case–control designs.
Table 4: Summary of findings from studies comparing dairy biomarkers and
clinical endpoints. Individual biomarkers have been broken out for CVD (15:0
and 17:0). Positive refers to reduced risk of disease. Abbreviations: CVD,
cardiovascular disease; T2D, type-2 diabetes
Endpoint Positive Neutral Negative
CVD 7 2 1
15:0 5 3 1
17:0 5 3 0
T2D 3 0 0
In the studies presented above, most found favorable correlations be-
tween dairy biomarkers and clinical endpoints relating to cardiometabolic
health (see Table 4). Although biomarkers can be regarded as more objective
measurements of dairy fat intake than questionnaire- or interview-based
methods, the methods used when employing this technique would benefit
from increased standardization, both regarding sampling sites and biomark-
ers. Adipose tissue samples are the best indicators of long-term intake, how-
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ever, in subjects with stable diets plasma PL samples are likely satisfactorily
valid as well, as long as the samples are taken after proper fasting.
Regarding the choice of biomarker, 15:0 is the most well-studied and
has been shown to be reliably correlated to dairy intake as assessed by other
methods in several studies, as well as in controlled feeding trials (Hodson
et al., 2014). Other biomarkers have also exhibited both reliability and
validity, but heterogeneity complicates meta-analyses and other comparisons
between studies. Due to the many inconsistencies described above, 14:0
should not be considered a biomarker of dairy fat intake. Endogenous
synthesis, often upregulated in subjects exhibiting poor metabolic health,
as evident by higher triglycerides, is likely a major confounder for this
biomarker.
Due to the inconsistent results found in several studies, the use of 17:0 as
a biomarker for dairy fat intake should be discouraged. The earliest reports
on using odd-chain SFAs as biomarkers reported weaker correlations for this
biomarker as well as for 15:0 + 17:0 combined, compared to 15:0 alone.
Although biomarkers are likely more objective measures of diet than
the commonly used FFQ and food diary methods, they are not free of
confounding. Changing one aspect of ones diet invariably alters another.
Consumption of dairy can be associated with other dietary or lifestyle
patterns that also influence cardiometabolic health. These confounders can
be culture-specific and heterogeneous. For example, high dairy consumption
can result from the consumption of cheese-rich processed food or ice cream
in cultures lacking a tradition of dairy consumption in its unprocessed form,
while at the same time being indicative of a traditional-type diet in countries
where dairy has historically been a major part of the cuisine.
Most of the studies included in this review have shown either protective
or neutral effects of dairy biomarkers in regards to clinical cardiometabolic
endpoints. Moreover, many studies have found positive or neutral correla-
tions between dairy biomarkers and different aspects of MetS. Although the
body of evidence is still quite small, it does not support the commonly stated
recommendation of replacing full-fat dairy products with low-fat varieties.
The complex and diverse nature of dairy products, as well as the conflicting
evidence presented above, suggests that dairy cannot simply be reduced to a
vehicle for SFAs.
Future research into dairy biomarkers could focus on at least a few
important aspects. First, for any large cohort where blood samples have
been stored and cardiometabolic endpoints followed up, dairy biomarkers
should be measured, and nested case–control studies should be conducted
for these endpoints. Second, to ascertain whether the link between dairy
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biomarkers and improved metabolic health is causal, proper longitudinal
studies where blood samples are taken at several time points can be used to
deduce which, if any, factors of MetS are influenced by dairy consumption.
Finally, the reliability and validity of 15:0 as well as other biomarkers needs
to be researched further, since most validation studies have used imprecise
methods of dietary assessment such as FFQs and interviews. Although
practicality and cost would limit the feasibility of validating adipose tissue
biomarkers under controlled conditions, such a study would be of great
value as well. Finally, the combination of biomarkers with other methods of
dietary assessment could provide improved means of measuring food intakes,
since combining two methods where errors occur independently of each
other can increase precision (Baylin et al., 2002). However, such a method
would likely be more expensive and time-consuming (ibid.), and a standard
protocol for such combined assessments remains to be developed.
Furthermore, future research into specific bioactive compounds present
in dairy products could be used as a basis for determining bovine breeding
strategies and optimizing manufacturing processes, as well as for identifying
potential targets for drug research.
6 Conclusion
The use of biomarkers for assessing dairy fat intake is growing among nutri-
tional epidemiologists, promising accurate and objective measures of dietary
intake, both current and retrospective. However, there are many facets of
dairy biomarker research that remain under-explored. Among these are
more stringent validations of several biomarkers, standardization of several
aspects such as the choice of compounds and FA pools used for sampling,
and development of a “gold standard” protocol employing several measures
of diet for increased statistical power.
Summarizing the evidence to date, a vast majority of prospective cohort
studies have found dairy fat consumption, as indicated by biomarkers, to be
either neutral or beneficial in regards to cardiometabolic health. In addition,
many cross-sectional studies have found beneficial associations between these
biomarkers and indices of cardiometabolic health. This stands in contrast
to prevalent dietary guidelines, that emphasize the choice of low-fat dairy
products where possible. Further research is needed to determine whether
these recommendations are conducive to public health.
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